Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2025

Shenzhu Pingxiao Formula treats allergic asthma through the HSP90AA1/MAPK14/PTGS2 pathway.

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJinling LuanXZXiaoxia Zhang

Discussion

Loading...

Member takes

Overview

Network pharmacology reveals key targets in allergic asthma treatment from shenzhu pingxiao formula, suggesting immune cell modulation.

Key Points

  • Administration of shenzhu pingxiao formula notably reduced airway hyperresponsiveness and immune cell presence.
  • Formula treatment decreased neutrophil recruitment, which is crucial in managing allergic asthma symptoms.
  • The study utilized molecular docking and real-time PCR to analyze key targets linked to the il-17 signaling pathway.
  • Key genes and proteins like hsp90aa1, mapk14, and ptgs2 were significantly influenced by the treatment, indicating its effectiveness.

Cite This Study

Luan et al. (2025) studied this question.

synapsesocial.com/papers/68d90a0a41e1c178a14f67fchttps://doi.org/10.1080/02770903.2025.2562582
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Human Neutrophils Couple Nitric Oxide Production and Extracellular Traps Formation in Allergic Asthma2024 · 7 citations
  2. 2The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study2022 · 171 citations
  3. 3Single‐cell transcriptomics of mouse lung reveal inflammatory memory neutrophils in allergic asthma2022 · 12 citations
  4. 4Development of eosinophilic inflammation is independent of B–T cell interaction in a chronic house dust mite‐driven asthma model2016 · 30 citations
  5. 5HSP90 Inhibition Suppresses Lipopolysaccharide-Induced Lung Inflammation In Vivo2015 · 30 citations